99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis
Status:
Completed
Trial end date:
2019-12-30
Target enrollment:
Participant gender:
Summary
Postmenopausal women with differentiated thyroid cancer (DTC) taking suppressive doses of
levothyroxine (L-T4) are thought to have accelerated bone loss and increased risk of
osteoporosis. Therefore, the investigators try to investigate the effects of
99Tc-MDP,alendronate sodium in postmenopausal women with DTC under TSH suppression and
osteoporosis.
Phase:
N/A
Details
Lead Sponsor:
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Treatments:
Alendronate Calcium Carbonate Cholecalciferol Ergocalciferols Methylene diphosphonate Vitamin D Vitamins